ASX Announcements
11 January 2021 | ResApp appoints VP, Commercial to progress growth strategy |
31 December 2015 | ResApp Files Pre-Submission Package with the US FDA |
14 December 2015 | ResApp Receives Approval to Begin Adult Study |
4 December 2015 | Release of Restricted Securities |
30 November 2015 | Results of Annual General Meeting |
25 November 2015 | CEO Presentation at Canary Networks Investor Roadshow |
16 November 2015 | Becoming a substantial holder |
11 November 2015 | US Roadshow - Investor Presentation |
10 November 2015 | Further Positive Preliminary Results from Clinical Study |
4 November 2015 | Exhibitor at McKinsey Global Integrated Care Conference |
30 October 2015 | Appendix 4C - Quarterly Sep 2015 |
28 October 2015 | Notice of Annual General Meeting/Proxy Form |
22 October 2015 | Dr Abeyratne to present at Pneumonia Innovations Summit |
20 October 2015 | TechKnow Invest Roadshow Presentation |
12 October 2015 | Appendix 3Y – Change of Director’s Interest Notice |
6 October 2015 | Australia Biotech Invest Presentation |
1 October 2015 | Appendix 4G |
1 October 2015 | Annual Report 2015 |
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.